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Abstract
BACKGROUND: Low-grade gliomas (LGG) of the brain have an uncertain prognosis, as many of them show continuous growth 
or upgrade over the course of time. We retrospectively investigated the role of positron emission tomography with 3’-deoxy-3’-
-[18F]fluorothymidine (FLT-PET) in the prediction of overall survival and event free survival in patients with untreated LGG. No 
such information is yet available in the literature.
MATERIAL AND METHODS: Forty-one patients with previously untreated LGG underwent 55 FLT-PET investigations during 
their follow-up because of subjective complaints, objective worsening of clinical conditions, equivocal findings or progression 
on magnetic resonance imaging. The time interval before referral for neurosurgical or radiation treatment was considered to be 
event free survival, the interval until death as overall survival, respectively. Standardized uptake values (SUV) were measured, 
and a 3-point scale of subjective assessment was also applied. ROC analysis was used to define cut-off values. The log rank 
test was used for comparison of Kaplan-Meier survival curves.
RESULTS: Eight patients (a total of 9 FLT-PET studies performed) died during follow-up. Progression leading to referral to 
therapy was recorded in 24 patients (a total of 33 FLT-PET studies). With a cut-off value of SUVmean = 0.236, a median overall 
survival of 1.007 days was observed in the test positive subgroup while median overall survival for the test negative subgroup 
was not achieved (p = 0.0002), hazard ratio = 17.6. Subjective assessment resulted in hazard ratio 11.5 (p = 0.0001). Only 
marginal significance (p=0.0562) was achieved in prediction of event free survival.
CONCLUSIONS: Increased FLT uptake in previously untreated patients with LGG is a strong predictor of overall survival. 
On the other hand, prediction of event free survival was not successful in our cohort, probably because of high prevalence 
of patients who needed treatment due to symptoms caused by a space-occupying lesion without respect to the proliferative 
activity of the tumour.
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Background
Gliomas comprise a heterogeneous group of neuroectodermal 
tumours that arise from the glia, the supporting cells of the central 
nervous system. Low-grade gliomas refer to tumours in either the 
grade 1 or grade 2 categories, depending on their histological 
characteristics. Brain low-grade gliomas include a diverse group 
of tumours with distinct characteristics, patterns of occurrence, 
response to treatment, and survival. Patients with low-grade glio-
mas tend to be otherwise healthy individuals of productive age, and 
management decisions, such as the timing of the intervention, ex-
tent of surgical resection, timing of radiotherapy, and the long-term 
benefits and risks of chemotherapy, have been controversial [1]. 
A strong positive correlation between uptake of radiolabeled 
3’-deoxy-3’-[18F]fluorothymidine (FLT) and levels of thymidine 
kinase-1 (TK1) was reported in vitro. Furthermore, it was demon-
strated that converting cells from growth arrest to a high growth 
rate consistently leads to elevated TK1 levels, accompanied by 
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increased FLT uptake. Taken together, these data validate FLT 
as a useful imaging agent for cell proliferation [2].
Positron emission tomography (PET) is a non-invasive imaging 
modality suitable for imaging FLT tissue distribution in vivo. Several 
clinically-oriented small-size studies concerning FLT-PET in human 
brain gliomas have been published to date. A significant correlation 
of FLT uptake with tumour grade and Ki-67 immunohistochemistry 
has been found in patients with newly diagnosed and recurrent 
gliomas [3–5]. The quantitative parameters of FLT uptake correlate 
with regional variations in cellular proliferation [6] and can help to 
differentiate between recurrent glioma and radiation necrosis [7, 8]. 
FLT-PET was used for survival predictions in patients with recurrent 
malignant glioma early after the start of therapy [9–11]. Overall 
survival in high-grade glioma was successfully predicted by 
FLT-PET-derived proliferative tumour volume [12]. 
No study dealing with prediction of overall survival or event 
free survival in untreated patients with low-grade gliomas has been 
found in the literature up to this point. Our work has concentrated on 
this topic with the aim of providing information that can potentially 
be used in decision-making for these patients.
Materials and methods
Patients and study design
Between August 2009 and September 2012 a total of 384 
FLT-PET brain investigations were routinely performed in 273 
patients at a single PET centre. All investigations were based on 
a clinical indication and were conducted in compliance with the 
Summary of Product Characteristics (SPC) of commercially avail-
able FLT. All patients signed their informed consent forms. Among 
them, patients with untreated low-grade gliomas were identified 
from the database for a retrospective analysis.
Inclusion criteria were the availability of feedback from the re-
ferring hospital and a diagnosis of low-grade gliomas established 
at any time prior to FLT-PET. The diagnosis of low-grade glio-
mas was based on magnetic resonance imaging findings. Typical 
conventional magnetic resonance imaging findings of low-grade 
gliomas were defined as relatively well-marginated usually homoge-
neous tumours that displayed little or no mass effect with minimal or 
no vasogenic oedema and little or no enhancement after contrast 
administration [13]. When a repeated magnetic resonance imaging 
was available, none or minimal enlargement was present over the 
time. Histologic evaluation was performed before FLT-PET in eight 
diagnostically uncertain cases and glioma grade II was confirmed.
Exclusion criteria were neurosurgical intervention in the brain 
except for diagnostic biopsy, results of a biopsy that excluded 
low-grade gliomas, radiotherapy of the brain or chemotherapy 
performed prior to a FLT-PET study.
Fifty-five consecutive studies in 41 patients (14 females, 
27 males) were identified. The age of the patients at the time of 
FLT-PET was 19.5–74.5 (M = 43.1, SD = 11.1) years. The indica-
tions for FLT-PET in this cohort were subjective complaints, objec-
tive worsening of their clinical condition and equivocal magnetic 
resonance imaging findings. All patients were in good clinical con-
dition; seizures and/or headache represented initial symptoms in 
majority of patients.
The study was performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and 
its later amendments. All procedures were in accordance with 
the ethical standards of institutional Ethical Committee on human 
experimentation.
FLT-PET acquisition and analysis
All patients were investigated early in the morning. Commer-
cially available FLT (3´-[18F]FLT, INJ, RadioMedic s.r.o., Czech 
Republic) was injected intravenously according to the patients’ 
weight in amounts varying from 161 to 323 (M = 227, SD = 42) MBq.
After an uptake time of 12–24 (M = 16.0, SD = 2.4) minutes, 
PET data acquisition was initiated using a Biograph 40 TrueV HD 
(Siemens, Germany) hybrid PET/CT scanner. Prior to this, a native 
low-dose CT of the head was acquired for the purpose of attenua-
tion and scatter correction of the PET scan. The CT scanning and 
reconstruction parameters were: 120 kV; 40 eff. mAs; slice 3 mm; 
pitch 1.2; rotation time 1 s; filtered back projection with H19s PET 
very smooth kernel, reconstruction increment 2 mm and transver-
sal field of view 300 mm. High resolution PET scanning directly 
followed the CT scan. PET and CT fields of view matched each 
other. The PET scanning and reconstruction parameters were: 3D 
mode; 1 bed position; 15 min. acquisition time; zoom 2; matrix 
size 256 × 256; iterative reconstruction with point spread function 
correction TrueX: 4 iteration, 21 subsets and Gaussian filter 2 mm. 
Transverse slices were archived using the dcm4chee.com picture 
archiving and communications system. 
Neither the original routine reports nor the magnetic resonance 
imaging images were used for the retrospective FLT-PET analysis. 
FLT-PET images were blindly re-evaluated using Rover software 
(ABX GmbH, Germany). Only an approximate tumour location (e.g. 
left fronto-temporal) was known a priori. In the event of any FLT 
uptake above normal brain background levels in the known tumour 
location, an ovoid mask was drawn around this area, excluding the 
choroid plexus and tissues outside the brain. Automatic region of 
interest (ROI) delineation was applied within this mask and its vol-
ume (VolFLT), maximum SUV (SUVmax), peak SUV (SUVpeak) and mean 
SUV (SUVmean), corrected for partial volume effect, was recorded. For 
ROI delineation and analysis a complex algorithm of Rover (adap-
tive thresholding) was used. In cases where the focus of intense 
FLT uptake occurred outside a known tumour location, it was also 
incorporated into the analysis. A cubic region of interest (ROI) of 
7.8–8.8 ml, representing normal brain background was drawn 
at a site opposite the tumour if possible, and its SUVmax, SUVpeak 
and SUVmean values were recorded. If not possible, i.e. in case of 
middle-line tumours as well as in case of no tumour appearance, 
this cubic ROI was arbitrarily placed in the right insular area.
Statistical analysis
To evaluate the prognostic value of FLT-PET, overall survival 
and event free survival were evaluated as clinical end-points. The 
date of the first clinical decision to start any therapy (neurosurgery, 
radiotherapy, chemotherapy) of low-grade gliomas after FLT-PET 
was recorded as well as the date of the death. The end-point of 
follow-up was March 2013 when the status (dead or surviving) 
of all patients was checked in the national register of the health 
insurance policyholders. Such information is freely accessible to 
health care institutions.
Overall survival was defined as the interval from FLT-PET 
investigation until death or end-point of follow-up in surviving pa-
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tients. Event free survival was defined as the interval from FLT-PET 
investigation until the first clinical decision to start any therapy for 
low-grade gliomas or end-point of follow-up.
Measured values of SUVmax, SUVpeak and SUVmean in the ROI 
of tumour served for the calculation of the tumour to background 
ratio (TBRmax, TBRpeak and TBRmean), where mean background SUV 
served as a denominator. Total lesion uptake (TLU) was calcu-
lated as a product of tumour ROI volume (VolFLT) and SUVmean. In 
cases where there was no tumour occurrence, tumour SUVmax, 
SUVpeak and SUVmean values were assigned to the values measured 
in the background ROI; in this situation TBRmax, TBRpeak and TBRmean 
were set to 1.0 and TLU and VolFLT were set to 0.0.
FLT-PET scans were also evaluated subjectively (Subj) using 
a 3-step scale. In cases where there was no tumour appearance 
Subj was set to 0 and it represented a negative test (Figure 1A). In 
findings with faint uptake just above normal brain background in 
a previously known tumour location Subj was set to 1 and it rep-
resented an equivocal test (Figure 1B). In all cases of abnormally 
elevated uptake of FLT, Subj was set to 2 and represented a positive 
test (Figure 1C).
The Youden index was used in the ROC analysis to determine 
the optimal cut-off value of SUVmax, SUVpeak, SUVmean, TBRmax, 
TBRpeak, TBRmean, VolFLT and TLU for predicting overall survival 
(dead vs. alive). This cut-off value served to establish the FLT-PET 
categorization as positive or negative. Survival curves based on 
FLT-PET categorization were obtained using the Kaplan-Meier ap-
proach and were compared using the log-rank test. Hazard ratio 
was expressed as well.
Probability values of p < 0.05 were considered as significant. 
When applicable, median (M), standard deviation (SD) and the 95% 
confidence interval (CI95) were calculated.
Results
During the course of the study, nine FLT-PET studies were per-
formed on eight patients, who died 115–1007 (M = 566, SD = 313) 
days after FLT-PET. Forty-six FLT-PET studies were performed on 33 
patients who survived for 234–1410 (M = 682, SD = 341) days after 
FLT-PET. In the 24 patients the decision to start therapy occurred 
15–811 (M = 185, SD = 258) days after 33 investigations and in 
17 patients no such decision occurred during follow up of 74–1373 
(M = 392, SD = 330) days. After the decision to start therapy, 
sixteen patients underwent operation, one of them additional 
radiotherapy and seven of them additional chemo-radiotherapy. 
Six patients were not surgically treated, four of them underwent 
radiotherapy and two patients had a combination of radiotherapy 
and chemotherapy. The record of therapy was not available in two 
patients. Seven of 24 patients died within 69–963 (median = 269) 
days after the referral to therapy. Progression of glioma was the 
cause of death in six of them, in one case the cause of death is not 
available due to the retrospective nature of the study. One patient 
did not receive any therapy and died 115 days after FLT-PET exa-
mination; the cause of his death is not known. 
In the background ROI, mean SUV ranged between 0.083– 
–0.237 (M = 0.152, SD = 0.034) and maximal SUV ranged between 
0.175–0.451 (M = 0.292, SD = 0.061).
Overall survival
Stepwise Cox proportional hazards regression was used to 
identify which of above mentioned parameters are independent 
predictors of overall survival. SUVmean was identified as the most sig-
nificant predictor and no other parameter was able to independently 
improve prediction (overall model fit significance level p = 0.0001). 
Table 1 shows the results of the ROC analysis. All param-
eters exhibit a significant ability to predict whether patients survive 
or die during the course of the study. The performance of SUVmean 
and Subj is significantly more accurate compared to TLU and VolFLT. 
No significant difference was found in the performance of the other 
parameters. Identified cut-off values were used for the categoriza-
tion of FLT-PET (positive vs. negative). These categories (posi-
tive/negative) were entered into the survival analysis.
Taking SUVmean = 0.236 as the cut-off value, 34 investiga-
tions were categorized as negative and 21 as positive. Median 
survival of 1007 days was observed in a test positive subgroup while 
median survival for a test negative subgroup was not established 
through the duration of our study. Kaplan-Meier survival curves are 
presented at Figure 2, with both curves differing significantly 
(p = 0.0002). The hazard ratio is 17.6 with CI95 = 4.3–72.0.
Figure 1. Various categories of subjective assessment (upper threshold was set to 10 % of the image maximum). A. Subj = 0, patient is event free 
for 794 days; B. Subj = 1, patient is event free for 1000 days; C. Subj = 2, event free survival was 44 days, patient died 1007 days after FLT-PET
A B C




Stepwise Cox proportional hazards regression identified SUVpeak 
as the most significant predictor of event free survival, but the model 
fit achieved only a marginal significance level p = 0.0539. At ROC 
analysis, no parameter exhibits a significant ability to define the 
moment when any therapy should be started.
Using the same categorization rule as in overall survival analy-
sis, i.e. SUVmean = 0.236 as the cut-off value, median event free sur-
vival was 281 days in the test positive subgroup and 643 days in the 
test negative subgroup. Kaplan-Meier survival curves are presented 
in Figure 3. Differences between both curves are only marginally 
significant (p = 0.0562), the hazard ratio is 1.9 with CI95 = 0.9–4.1.
Subjective assessment
From a practical point of view, the subjective analysis of 
these images is of great importance and their predictive value 
was therefore also analyzed. In 28 cases there was no subjectively 
detectable FLT uptake higher than natural brain background (ca-
tegory 0). With previous knowledge of approximate localization of 
the tumour, faint FLT uptake hardly distinguishable from the brain 
background was found in 11 cases (category 1). Easily identifiable 
focal pathological FLT uptake was present in 16 cases (category 2). 
Median overall survival was 1007 days in category 2, while in other 
categories it was not established during the time span of the study. 
Kaplan-Meier survival curves are presented in Figure 4. There 
was no significant difference between overall survival curves of 
category 0 and 1, while both significantly differed from category 2 
(p = 0.005 and p = 0.0445, respectively) with hazard ratios of 15.9 
(CI95 = 3.5–71.3) and 6.6 (CI95 = 1.6–25.6), respectively. When ana-
lyzing categories 0 and 1 together against category 2, the hazard 
ratio for overall survival was 11.5 (CI95 = 2.5–54.2).
Median event free survival was 500 days in category 0, 752 
days in category 1 and 132 days in category 2. Kaplan-Meier 
survival curves are presented at Figure 5. No significant differ-
ences were found between curves representing event free survival.
Table 1. Results of ROC analysis of different parameters in relation to overall survival. Descendent order according to the area under the curve (AUC)
Parameter Cut-off Sensitivity (%) Specificity (%) AUC p
SUVmean 0.236 88.9 71.7 0.857 0.0001
SUVpeak 0.287 88.9 71.7 0.816 0.0001
Subj 1.000 77.8 80.4 0.812 0.0001
SUVmax 0.565 77.8 80.4 0.806 0.0001
TBRmean 2.218 77.8 73.9 0.793 0.0003
TBRpeak 1.807 88.9 63.0 0.771 0.0045
TBRmax 2.355 88.9 60.9 0.742 0.0182
TLU 0.356 88.9 67.4 0.714 0.0069
Vol 0.479 88.9 63.0 0.685 0.0200
Figure 2. Overall survival: Kaplan-Meier curves for FLT-PET 
categorized according to SUVmean = 0.236 as a cut-off value. Both 
curves differ significantly (p = 0.0002)
Figure 4. Overall survival: Kaplan-Meier curves for FLT-PET 
categorized according to subjective assessment. Curves of both 
categories 0 and 1 significantly differ from category 2
Figure 3. Event free survival: Kaplan-Meier curves for FLT-PET 
categorized according to SUVmean = 0.236 as a cut-off value. Both 
curves differ with marginal significance (p = 0.0562)
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Discussion
We are not able to compare our results with results of other 
studies, as we found no references to any similar study in the 
literature. No survival analysis dealing with a homogenous group 
of patients with low-grade gliomas undergoing FLT-PET before 
therapy is available. Previously published papers have dealt with 
gliomas of various grades [3–5] or with different timing during their 
management (before/after therapy). Other studies concentrated 
on predictions of prognosis in treated high-grade gliomas [9–11]. 
The lack of comparable studies can be explained by a relatively 
rare occurrence of low-grade gliomas in the population and the 
limited availability of FLT-PET. We were able to conduct this study 
thanks to 1. the close collaboration of two hospitals specialized in 
neurooncosurgery, where a large proportion of patients with brain 
tumours are concentrated; 2. commercially and regularly available 
registered FLT; 3. the full reimbursement of FLT-PET by a national 
mandatory health insurance system.
It is known that brain tumour uptake is determined on the 
one hand by the proliferative activity of tumour cells and on the 
other hand by a nonspecific leakage of FLT through the impaired 
blood-brain barrier (BBB). Kinetic modelling is essential to distin-
guish both processes and SUV measurement is not sufficient for 
the assessment of net proliferative activity [14]. This is of great 
importance in high grade gliomas and especially after treatment, 
when impairment of the BBB occurs regularly. On the other hand 
impairment of the BBB is a rare finding in untreated low-grade 
gliomas on magnetic resonance imaging. Taking this fact into 
consideration and because kinetic modelling is not applicable to 
daily routine, we did not apply it.
Besides dynamic studies concentrated on kinetic modelling of 
FLT, an uptake time of 60 minutes was used in the majority of the re-
maining studies. We routinely apply a 15 minute uptake time based 
on findings by Chen et al. [16] that FLT uptake in gliomas is rapid, 
peaking at 5–10 minutes after injection and remaining stable for 
up to 75 minutes. The advantage of this approach is to lower the 
fraction of FLT conjugated with glucuronide [16] and, theoretically, 
to lower the unspecific uptake due to an impaired BBB.
We decided to use the date when neurosurgery, radiotherapy 
or chemotherapy was recommended as the considerable event, 
i.e. time of progression. This date was easily retrievable from the 
information system and we consider it to be the most objective 
approach, because the decision is based on multidisciplinary 
neurooncologic consultation. The weakness of this approach 
is the partial influence of FLT-PET itself on disease management 
decision-making, because its results were also considered at 
consultation. We found only marginally significant relation between 
FLT-PET and event free survival.
FLT-PET represents a very strong predictive factor for overall 
survival. Based on this, we believe FLT-PET also has a predictive 
power for event free survival in general, but we were unable to 
clearly demonstrate this in our study. We assume that this was due 
to a high prevalence of patients with mass effect at the time of the 
FLT-PET investigation, who all consequently received treatment 
that disregarded the FLT-PET result. To demonstrate the predictive 
value of FLT-PET for event free survival, we would need to enlarge 
the cohort of those patients who have no clinical symptoms at the 
time of FLT-PET.
Conclusion
We have brought evidence that FLT-PET can predict overall 
survival in previously untreated patients with suspicious or histologi-
cally confirmed low-grade glioma. Patients without any identifiable 
FLT uptake or with hardly distinguishable FLT uptake in the tumour 
region have good prognosis, while patients with clearly visible 
pathologic FLT uptake have a 12 times higher risk of death despite 
the standard treatment. The prediction value of the subjective as-
sessment was not significantly improved by a semi-quantitative 
assessment, including SUVmean. Based on this work, we can re-
commend inclusion of FLT-PET into further clinical studies aiming 
to identify the most important predictors of survival in patients with 
untreated low-grade gliomas.
On the other hand we were not able to bring robust data to 
confirm FLT-PET as a test capable of predicting event free survival. 
We assume that this difference can be explained by the fact that 
patients undergoing FLT-PET often had symptoms derived from 
space-occupying lesions only and were therefore referred for treat-
ment which disregarded the FLT-PET result.
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